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ABSTRACT 
A research project designed to investigate changes in maximal oxygen consumption (VO2max) 
during and following long duration flight on the International Space Station (ISS) has recently been 
completed.  The device used to measure oxygen consumption (VO2) on board ISS, the Portable 
Pulmonary Function System (PPFS) manufactured by the Danish Aerospace Corporation (DAC), is 
based on previous-generation devices manufactured by DAC, but the PPFS has not been validated for 
analyzing metabolic gases or measuring cardiac output (Qc).  The purpose of the present evaluation is to 
compare PPFS metabolic gas analysis measurements to measurements obtained using a clinically-
validated system (ParvoMedics TrueOne© 2400 system; Parvo).  In addition, Qc data collected with the 
PPFS were compared to Qc measurements from echocardiography.  METHODS: Ten subjects 
completed three cycle exercise tests to maximal exertion.  The first test was conducted to determine each 
subject’s VO2max and set the work rates for the second and third (comparison) tests.  The protocol for 
the two comparison tests consisted of three five-minute stages designed to elicit 25%, 50%, and 75% 
VO2max (based upon results from the initial test), followed by one-minute stages of increasing work rate 
(25 watts/minute) until the subject reached maximal effort.  During one of the two comparison tests, 
metabolic gases and Qc were assessed with the PPFS; metabolic gases and Qc were assessed with the 
Parvo and by echocardiography, respectively, during the other test.  The order of the comparison tests 
was counterbalanced.  VO2max and maximal work rate during the comparison tests were compared 
using t tests.  Mixed-effects regression modeling was used to analyze submaximal data.  RESULTS: All 
of the data were within normal physiological ranges.  The PPFS-measured values for VO2max were 6% 
lower than values obtained with the Parvo (PPFS: 3.11 ± 0.75 L/min; Parvo: 3.32 ± 0.87 L/min; mean ± 
standard deviation; P = 0.02); this difference is probably due to flow restriction imposed by the PPFS Qc 
accessories.  Submaximal VO2 values were slightly lower when measured with the PPFS, although 
differences were not physiologically relevant.  The PPFS-measured values of submaximal carbon 
dioxide production (VCO2) were lower than the data obtained from Parvo, which could be attributed to 
lower fractions of expired carbon dioxide measured by the PPFS.  The PPFS Qc values tended to be 
lower than echocardiography-derived values.  CONCLUSIONS: The results of the present study 
indicate a need to further examine the PPFS and to better quantify its reproducibility; however, none of 
the findings of the current evaluation indicate that the PPFS needs to be modified. 
 
 
INTRODUCTION 
 The National Aeronautics and Space Administration (NASA) Human Research Program (HRP) 
has developed an integrated research plan to address the health risks that might impede human 
exploration beyond Earth’s orbit (Human Research Program Integrated Research Plan, NASA HRP 
47065).  One of the risks identified by NASA’s Integrated Research Plan is the “Risk of reduced 
physical performance capabilities due to reduced aerobic capacity.” 
Maximal oxygen uptake (VO2max), also known as aerobic capacity, is the maximal rate at which 
a person can consume oxygen (O2) during exercise, and is directly related to the ability to perform 
prolonged and strenuous work (1, 2).  There is clear evidence from bed rest studies (10) and short-
duration spaceflight that VO2max is reduced after exposure to both simulated and actual microgravity 
(12, 16), particularly when minimal or no exercise is performed during the exposure period.  However, 
results from longer spaceflight missions, based upon submaximal exercise test results, have been less 
clear.  During the Skylab missions, submaximal exercise testing was performed approximately every six 
days, and there appeared to be no overall trend (increase or decrease) in the heart rate (HR) response to 
standard exercise work rates (up 75% of pre-flight VO2max).  These results were interpreted to indicate 
that VO2max was unchanged during missions up to three months in duration (14, 15, 21).  Similar 
submaximal exercise tests were performed each month during early ISS missions.  In contrast to Skylab 
results, ISS crewmembers experienced an elevated HR response to exercise in the first weeks of the 
mission, which suggested that VO2max may have been compromised, but there appeared to be some 
recovery over the course of a six-month mission (18).  In the first week after landing, the HR responses 
to exercise of both the Skylab and ISS crew members were elevated, which is consistent with a decline 
in VO2max.  Multiple factors other than aerobic deconditioning can influence the HR response to 
exercise and given the error in estimating VO2max from submaximal exercise data (11), it was unclear 
until recently (16) how much, or even if, VO2max is affected by long-duration spaceflight. 
Oxygen uptake during exercise (VO2) is influenced by both central (related to the heart) and 
peripheral (related to O2 extraction and distribution of blood flow in the muscle tissues) factors.  The 
relationship between these factors is expressed in a relation commonly known as the Fick equation (20): 
VO2 = Qc (a-v)O2 difference 
in which cardiac output (Qc) is the amount of blood pumped from the heart’s left ventricle per minute 
and is the product of HR and the volume of blood ejected from the left ventricle per beat (also known as 
stroke volume [SV]).  Arterial to venous O2 difference “(a-v)O2” is the difference between O2 levels in 
the arterial and venous blood, i.e. O2 extraction of the tissues.  Thus, any factor that influences HR, SV, 
or O2 extraction may influence VO2 or VO2max. 
A contractor to the European Space Agency, Damec Research ApS (currently named Danish 
Aerospace Corporation [DAC]), developed a metabolic gas analysis system capable of measuring VO2 
on board ISS.  This device, named the Portable Pulmonary Function System (PPFS), was used to 
measure astronauts’ VO2max during long-duration space flight (16).  The current report describes our 
efforts to validate measurements obtained from the PPFS by comparing PPFS measurements of 
metabolic gas analysis obtained during exercise tests with equivalent measurements obtained using the 
ParvoMedics TrueOne© 2400 system (ParvoMedics, Sandy, UT).  The ParvoMedics system has been 
validated (8) for accurate measurement of VO2 and has been used in the Exercise Physiology Laboratory 
at NASA Johnson Space Center since 2004 but was not designed for use on ISS.  The second purpose of 
the present study was to compare the non-invasive measurements of Qc obtained by the PPFS to 
measurements obtained using echocardiography. 
  
-- -- --
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METHODS 
Subjects 
Ten healthy volunteers participated in the ground-based study described here (Table 1).  Subjects 
passed a modified Air Force Class III physical exam before they participated in the study and received 
written and verbal explanations of test protocols before providing written informed consent.  The NASA 
Johnson Space Center Committee for the Protection of Human Subjects reviewed and approved the test 
protocols and procedures. 
TABLE 1: SUBJECT CHARACTERISTICS (MEAN ± SD) BY SEX. 
  Male Female 
n  6 4 
Age (yr)  37.5 ± 9.5 36.0 ± 9.2 
Weight (kg)  80.1 ± 10.6 55.6 ± 2.6 
Height (cm)  180.8 ± 4.3 162.6 ± 4.1 
VO2max (ml/kg/min)  48.7 ± 9.3 46.2 ± 5.0 
 
Overall Protocol 
Subjects performed three peak cycle tests to measure VO2max.  The LODE Excalibur Sport 
(Groningen, NL) cycle ergometer was used for all testing. 
The initial peak cycle test used the same protocol used to measure the pre-flight VO2max in 
astronauts before early ISS missions (18).  During the initial test, subjects with a body mass of > 65 kg 
cycled for three minutes each at 50, 100, and 150 watts (W), after which work rate was increase 25 
W/minute until maximal exertion.  If the subject’s body mass was < 65 kg, the subjects cycled for three 
minutes each at 50, 75, and 100 W, after which work rate increased 25 W/minute until maximal exertion.  
If an individual who was <65 kg reported that they regularly participated in cycle exercise, the first 
protocol described above was used for this initial test.  For either protocol, the work rate was increased 
until subjects indicated that they could no longer continue or until they could no longer maintain a pedal 
cadence of 75 revolutions per minute.  During this initial test, the ParvoMedics TrueOne© 
(ParvoMedics, Salt Lake City, UT) system was used to perform metabolic gas analysis.  The VO2 and 
work rate data from the initial test were used to design the protocol for the second and third 
(comparison) tests. 
The second and third tests were designed to compare the metabolic gas analysis and Qc 
measurements from the two different devices.  The testing protocol for these comparison tests was based 
on the submaximal cycle test used by Skylab astronauts (14, 15, 21) and for the ISS Periodic Fitness 
Evaluation during early ISS mission (18), but the protocol was extended to achieve VO2max.  
Specifically, the protocol for the comparison tests consisted of three five-minute stages designed to elicit 
25%, 50%, and 75% of the individual’s VO2max that was previously determined from the initial peak 
cycle test.  The three initial stages were followed by work rate increases of 25 W/minute until subjects 
reached their maximal effort.  This is the same exercise protocol that was used in a study of ISS 
astronauts (16).  Comparison tests were performed in a counterbalanced order; one test was performed 
using the ParvoMedics TrueOne© system paired with echocardiography to measure Qc, and one test was 
performed using the PPFS to obtain metabolic gas analysis data and Qc measurements using a 
rebreathing technique.  These tests were repeated within one month of the initial test, and the two tests 
were separated by at least one week to minimize the potential effects of residual soreness or fatigue. 
Before starting the exercise, the subjects rested quietly for five minutes in supine and seated 
positions while measurements of HR, heart rhythm, and blood pressure (BP) were taken.  HR and 
rhythm were measured electrocardiographically (Q-Stress, Quinton Instruments, Seattle, WA), and BP 
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was measured using a mercurial sphygmomanometer and stethoscope.  HR, heart rhythm, and metabolic 
expired gas were measured continuously throughout the test.  BP was measured once during each 
submaximal exercise stage, and ratings of perceived exertion (5) were reported during the last 30 
seconds of each stage.  BP was recorded during the recovery period after the test, and the subject was 
monitored for any adverse effects caused by maximal physical exertion. 
Metabolic Gas Analysis Systems 
The dependent variables for comparisons between the two systems were VO2, carbon dioxide 
production (VCO2), expired ventilation (VE), and fractions of expired oxygen and carbon dioxide (FEO2 
and FECO2). 
ParvoMedics TrueOne© system uses a paramagnetic O2 analyzer (operating range 0-25% O2) 
and an infrared single-beam, single-wavelength, carbon dioxide (CO2) analyzer (operating range 0-15% 
CO2) to measure the composition of expired gases.  The subjects inspired through a two-way non-
rebreathing valve (Hans Rudolph Model 2700, Kansas City, MO) and expired air composition was 
sampled from a four-liter mixing chamber.  The inspired gas composition was assumed to be standard 
atmospheric values (i.e., 20.93% O2 and 0.03% CO2).  VE was measured using a Hans Rudolph Model 
3813 linear pneumotachometer (operating flow range 0-800 L/min).  Computational software was 
provided with the system.  Data were collected continuously by the ParvoMedics system and were 
averaged in 30-second intervals to the nearest whole breath.  VO2max was accepted as the highest VO2 
attained for a single 30-second period. 
The PPFS uses two types of technology for gas analysis.  A photoacoustic method of gas analysis 
is used to measure CO2 concentration.  In this technique, the gas sample is exposed to intermittent 
infrared light.  The gas sample absorbs the light, and the heat from the absorbed energy results in an 
increase in pressure in the sample chamber.  The intermittent infrared light is divided into different 
pulsation frequencies and is filtered optically.  Each optical filter allows only specific wavelengths of 
light to pass through.  The wavelengths correspond to the infrared absorption spectra of the sample 
gases.  When the light source is removed the gas cools down, resulting in a pressure fluctuation.  
Because the pulsation frequency is in the audible range, the pressure fluctuation becomes an acoustic 
signal that is detected by a microphone.  The sounds recorded by the microphone are analyzed, and the 
amplitude of each signal is used to calculate the gas concentration.  The PPFS operating range for CO2 
concentration is from 0% to12%.  An Oxigraf™ sensor in the PPFS is used for O2 analysis.  The 
Oxigraf™ uses a spectroscopy technique for laser diode absorption in which the sample gas is exposed 
to a laser with a wavelength of 760 nm (the peak of O2 absorption).  The laser signal is attenuated in 
proportion to the concentration of O2 present in the sample.  The PPFS operating range for O2 is from 
0% to 100%.  When using the PPFS during exercise testing, the subject inspires through a DAC custom-
designed two-way non-rebreathing valve and the expired gases are sampled in a 15-liter anesthesia bag 
that serves as a mixing reservoir.  Ventilation is measured on the inspired side of the non-rebreathing 
valve using a DAC custom-designed pneumotach (operating flow range 0-900 L/min).  The technologies 
used for PPFS metabolic gas analysis are further described by Clemensen and colleagues (6).  A 
proprietary software package developed by DAC, named ADAM, was used to compute metabolic gas 
analysis variables.  Similar to the Parvomedics data reduction, the data were averaged in 30-second 
intervals to the nearest whole breath. 
Cardiac Output Measurements 
To obtain Qc measurements from echocardiography, two-dimensional imaging was used to 
obtain the aortic annulus diameter (d) from the parasternal long axis during supine rest before the 
exercise tests.  Continuous-wave Doppler from the apical window (2- to 4-MHz phase array probe, iE33, 
Phillips Ultrasound, Andover, MA) was used to obtain aortic blood velocity time integral in three to five 
heartbeats during the last minute of rest and each five-minute exercise stage.  Images were stored 
digitally for offline analysis and independently analyzed by two experienced, registered sonographers.  
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Aortic annulus area (π•d2/4), stroke volume (annulus diameter x velocity time integral), and Qc (stroke 
volume x heart rate) were calculated. 
Qc measurements using the PPFS involved subjects rebreathing into and out of a bag containing 
2.5-3.5 liters of a gas composed of 1% Freon R-22, 1% sulfur hexafluoride (SF6), 40% O2, and 58% N2.  
The subjects started the rebreathing procedure after an exhalation at a self-selected time point during 
seated rest and within the last minute of each five-minute stage of exercise.  The rebreathing protocol 
consisted of eight breaths (approximately 30 seconds during rest and 20 to 25 seconds during exercise).  
The ADAM software calculated Qc using formulas that are described elsewhere (4). Briefly, Qc was 
calculated using the rate of disappearance of Freon R-22 (a blood-soluble gas) from the rebreathed air as 
measured from the end-tidal expiratory gas fractions.  Adequate gas mixing in the lungs, required for 
accurate Qc measurements, was determined by measuring the end-tidal expiratory gas fractions of SF6 (a 
blood-insoluble gas).  Freon R-22 and SF6 were sampled through a Nafion® catheter connected to a port 
adjacent to the mouthpiece of the PPFS. 
Statistical Methods 
The PPFS measures were compared to those obtained with the Parvomedics device using 
expected and actual responses to a range of workloads experienced by the subjects during submaximal 
exercise.  To achieve this comparison, we used mixed-effects regression models (7) to estimate the mean 
output of gas measurements (VO2, VCO2, VE, FEO2 and FECO2) obtained on the Parvomedics device as 
either a linear or a quadratic function of work rate (depending on the type of output), allowing for 
random subject differences and within-subject measurement errors.  We then used another mixed-effects 
regression model to estimate the bias (mean difference between the two devices: PPFS − Parvomedics) 
as a function of the mean.  From this second regression model, we also calculated 95% confidence limits 
for the bias, which are displayed for each of the measurements.  The plots are similar to Bland-Altman 
plots (3), except that in our case, by modeling the physiological responses as functions of workload, we 
make allowance for repeated measures on subjects as well as reduce sensitivity to the effect of 
measurement errors in the standard device (in this case, the Parvomedics).  The mean VO2max and 
maximal work rate attained during the tests with each device were also compared using paired t tests. 
The analysis of the PPFS and echocardiographic Qc and SV data followed a strategy similar to 
that used for the metabolic gas analysis comparisons, with one important difference: because there is no 
compelling evidence in the literature to suggest that either of the methods should serve as a standard 
(17), the data collected from each device was modeled as a function of cycle ergometer work rate. 
RESULTS 
Submaximal Exercise 
All of the metabolic gas analysis data, irrespective of the device used for measurement, were 
within normal physiological ranges.  Thus, there were no gross errors in output from either the PPFS or 
the Parvomedics system. 
Comparisons of the absolute VO2 values measured by the two devices are shown in Figure 1.  In 
general, the PPFS-measured values were lower than those measured by the Parvomedics system. 
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Figure 1.  VO2 values observed during the submaximal stages of testing.  The left panel displays the observed differences 
(PPFS-Parvomedics) between the two devices.  Expected VO2 (x-axis) for each exercise level is predicted from the 
relationship between VO2 and work rate for these subjects, as measured by the Parvomedics (the “clinical standard” device).  
The numbers displayed next to the data points are subject identifiers (three data points for each subject).  The gray shaded 
area indicates ±5% of the expected VO2.  The solid straight line is the mean relationship, and the curves are 95% confidence 
intervals for the mean difference.  The right panel displays the relationship between the VO2 values of the two devices 
evaluated.  The solid line is the line of identity. 
The VCO2 data are displayed in Figure 2.  As was the case for VO2, the PPFS values were lower 
than the data measured by the Parvomedics system.  The disparity between the two devices increased as 
the values of VCO2 rose. 
  
  
Figure 2.  VCO2 values observed during the submaximal stages of testing.  The left panel displays the observed differences 
(PPFS-Parvomedics) between the two devices.  Expected VCO2 (x-axis) for each exercise level was predicted from the 
relationship between VCO2 and work rate for these subjects, as measured by the Parvomedics device.  The numbers displayed 
next to the data points are subject identifiers (three data points for each subject).  The solid straight line is the mean 
relationship, and the curves are 95% confidence intervals for the mean difference.  The right panel displays the relationship 
between the VCO2 values of the two devices evaluated.  The solid line is the line of identity. 
Figure 3 illustrates the ventilation data.  The values from the PPFS and the Parvomedics were 
quite close; the 95% confidence intervals of the difference between the two devices contained zero (no 
difference) throughout the range of data observed in the evaluation. 
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Figure 3.  VE values observed during the submaximal stages of testing.  The left panel displays the observed differences 
(PPFS-Parvomedics) between the two devices.  Expected VE (x-axis) for each exercise level is predicted from the relationship 
between VE and work rate for these subjects, as measured by the Parvomedics.  The numbers displayed next to the data points 
are subject identifiers (three data points for each subject).  The solid straight line is the mean relationship, and the curves are 
95% confidence intervals for the mean difference.  The right panel displays the relationship between the VE values of the two 
devices evaluated.  The solid line is the line of identity. 
The FEO2 measured by each device was fairly comparable (Figure 4).  At the very lowest levels, 
the 95% confidence interval was slightly above a difference of zero, which indicates that the PPFS 
values were slightly higher than the Parvomedics values.  This would cause computed VO2 values from 
the PPFS to be lower. 
  
  
Figure 4.  FEO2 values observed during the submaximal stages of testing.  The left panel displays the observed differences 
(PPFS-Parvomedics) between the two devices.  Expected FEO2 (x-axis) for each exercise level is predicted from the 
relationship between FEO2 and work rate for these subjects, as measured by the Parvomedics.  The numbers displayed next to 
the data points are subject identifiers (three data points are present for each subject).  The solid straight line is the mean 
relationship, and the curves are 95% confidence intervals for the mean difference.  The right panel displays the relationship 
between the FEO2 values of the two devices evaluated.  The solid line is the line of identity. 
FECO2 values are illustrated in Figure 5.  The PPFS values were clearly lower than the 
Parvomedics values across the range of data produced by our subjects. 
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Figure 5.  FECO2 values observed during the submaximal stages of testing.  The left panel displays the observed differences 
(PPFS-Parvomedics) between the two devices.  Expected FECO2 (x-axis) for each exercise level is predicted from the 
relationship between FECO2 and work rate for these subjects, as measured by the Parvomedics.  The numbers displayed next 
to the data points are subject identifiers (three data points for each subject).  The solid line is the mean relationship, and the 
curves are 95% confidence intervals for the mean difference.  The right panel displays the relationship between the FECO2 
values of the two devices evaluated.  The solid line is the line of identity. 
Maximal Exercise 
The average VO2max attained by the subjects was higher when measurements were obtained with the 
Parvomedics device (Figure 6).  The higher Parvomedics VO2max also was associated with a higher 
peak work rate attained during testing. 
 
Figure 6.  Mean VO2max (left panel) and maximal cycle work rate (right panel) attained during the tests using the 
Parvomedics and PPFS devices.  Note that the PPFS trial produced a lower VO2max in almost direct proportion to the lower 
work rate attained. 
Cardiac Output 
The Qc values obtained from the PPFS and echocardiographically are displayed in Figure 7.  At resting 
levels the two methods provided comparable data; however, with increasing exercise work rate the 
echocardiographic data were lower than the associated PPFS data. 
Parvomedics PPFS
V
O
2 
m
ax
 (L
/m
in
)
0
1
2
3
4
5
p = 0.02
-6.1%
Parvomedics PPFS
M
ax
im
al
 W
or
k 
Ra
te
 (w
at
ts)
0
100
200
300
400
p < 0.01
-6.7%
· 4•& - - -.-12- - - - _ .. 1,2. - - - •_9 - - - - - - - -
• 12 
., 
., e 3 
., 
., 
• 8 
• 11 
. ,
4.2 4.4 4.6 
Expected FECO, (%) 
i 
e s 
4.8 
T 
CJ 
'ii i.n 
';:;' ~ 
0 
u 
w 
LL 
t2 ... 
a. 
a. 
.. 
3.5 
.. . 
• I• 
\ 
4 Parvomedics i·~co2 (%) 5.5 
i T 
CJ 
 14 
  
  
Figure 7.  QC values observed during the submaximal stages of testing.  The left panel displays the differences (PPFS-
Echocardiograph) observed between the two devices across exercise work rates (0 W = seated rest).  The numbers displayed 
next to the data points are subject identifiers (three data points for each subject).  The solid straight line is the mean 
relationship, and the curves are 95% confidence intervals for the mean difference.  The right panel displays the relationship 
between the QC values of the two methods evaluated.  The solid line is the line of identity. 
Figure 8 contains the SV data from the echocardiograph and the PPFS.  Stroke volume tended to 
be higher when measured by echocardiography, with the margin of the upper 95% confidence interval 
falling close to no difference across the range of values measured. 
  
  
Figure 8.  SV values observed during the submaximal stages of testing.  The left panel displays the differences (PPFS-
Echocardiograph) observed between the two devices across exercise work rates (0 W = seated rest).  The numbers displayed 
next to the data points are subject identifiers (three data points for each subject).  The solid straight line is the mean 
relationship, and the curves are 95% confidence intervals for the mean difference.  The right panel displays the relationship 
between the SV values of the two methods evaluated.  The solid line is the line of identity. 
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DISCUSSION 
The primary purpose of this study was to determine whether consistent differences existed 
between two metabolic gas analysis systems, PPFS and Parvomedics, with respect to measuring VO2 
during submaximal and maximal exercise.  We also assessed differences between Qc measurements 
obtained with the PPFS and by echocardiography. 
Our data show statistically significant differences between the PPFS and Parvomedics values of 
VO2 during submaximal exercise at loads up to 75% VO2max (Figure 1), but this difference is not of 
sufficient magnitude to be physiologically important.  The average differences observed in submaximal 
VO2 were just outside the 4%-6% intra-individual day-to-day variation in VO2 commonly reported in the 
literature (19).  The upper 95% confidence interval computed from the differences between the two 
devices was not outside of the 4%-6% range.  However, when measurements are repeated across the 
duration of a longitudinal study, it is important that all measurements (e.g., before, during, and after 
space flight) be conducted using the same device to avoid potential sources of error associated with 
different metabolic gas analysis systems. 
It appears that the difference in submaximal VO2 values was not caused by different measures of 
VE obtained by the two devices (Figure 3).  This suggests that FEO2 measurements might explain the 
VO2 differences; conceptually VO2 is simply the product of VE and the difference in O2 concentration 
between ambient air and expired air.  However, it is difficult to pinpoint this as the precise cause of the 
discrepancy in VO2 values because the preponderance of the FEO2 data is clustered within a narrow 
range between 16 and 16.5% O2 (Figure 4).  FECO2 also contributes to the calculation of VO2, but its 
influence is negligible compared to FEO2 or VE.  To illustrate, at a VO2 of 4.68 L/min (a level 
representative of maximal exercise of our fittest subjects) if FECO2 was reduced by 0.4% (which is the 
average difference observed in FECO2 between the two devices in our tests; Figure 5), the calculated 
VO2 would be reduced only to 4.66 L/min. 
Mean VO2max obtained from the two devices was significantly different (Figure 6).  However, 
this is not likely due to any measurement problems within the devices per se, in light of the fact that the 
6.1% lower VO2max measured with the PPFS was observed in combination with a 6.7% reduction in the 
peak work rate attained during the PPFS tests.  The reduction in work rate achieved by the subjects 
during the PPFS comparison test might be due to a ventilatory flow restriction imposed by the PPFS.  
When using the PPFS, the subjects breathe through a valve and a mouth port tube that is lengthened to 
accommodate the Qc rebreathing bag adapter and the pneumatic valve, which controls flow into and out 
of the bag.  The extended length of the port tube causes more flow limitation and resistance to breathing 
than the standard Hans Rudolph 2700 valve that is part of the Parvomedics device.  Pressures in the 
respiratory valve up to 13.5 cmH2O were measured by the PPFS during peak exercise, and the pressure 
during submaximal exercise ranged from 2 to 5 cmH2O.  A peak pressure of about 8 cmH2O is expected 
at peak exercise ventilation values when using the Hans Rudolph 2700 valve 
(http://www.rudolphkc.com/pdf/691017%201008%20I.pdf).  The pressures measured by the PPFS do 
not seem to be in the range that would cause marked limitation to submaximal exercise, although 
ventilation at maximal exercise levels may be impaired (9), thus limiting performance. 
The differences in VCO2 values obtained from the two devices (Figure 2) are likely to be directly 
attributable to the different FECO2 data (Figure 5).  The primary contributing variables used in the 
calculation of VCO2 are VE and FECO2. As noted above, VE measurements did not differ significantly 
between the two devices.  The disparity between FECO2 values measured by the Parvomedics device 
and the PPFS are not easily explainable because both systems use infrared measuring techniques for 
detecting CO2 concentrations. 
Qc and SV values obtained during exercise using the PPFS are lower than the measurements 
obtained by echocardiography (Figures 7 and 8).  As noted in the statistical methods section of this 
report and in previous reports (17), there is no compelling evidence to suggest that one technique is more 
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accurate or valid than the other.  However, in the present study, measurement of SV and Qc using 
echocardiography involved analysis of as few as three heart beats, whereas about 20 to 40 heart beats 
would occur during the rebreathing technique used for the PPFS.  In addition, it becomes increasingly 
difficult to attain accurate ultrasound images with increasing cycle work rate because of subject 
movement.  Thus, it is possible that the rebreathing technique was less prone to variation than 
echocardiography because beat-to-beat differences in SV are averaged over more heart beats and subject 
movement does not affect the measurement. 
Limitations 
An ideal comparison of metabolic gas analysis systems would entail the two systems being 
operated “in series” (i.e., measuring fractions and volumes of the same expired gases or from sensors in 
close proximity to one another) on the same subject.  An “in series” evaluation eliminates day-to-day 
variation in the subjects’ response to exercise as a source of error.  However, this type of setup often is 
not feasible because the two systems can interfere with each other and produce erroneous results.  
Discussions with the manufacturers of both the Parvomedics system and the PPFS led us to conclude 
that an evaluation with the two devices in series may lead to errors, particularly in gas sampling, and 
therefore our tests were performed using the devices on separate days.  With this approach, valid 
comparisons of the VO2 and VCO2 data obtained from each device are still possible, although variables 
associated with the calculation of VO2 and VCO2 (i.e., FEO2, FECO2 and VE) need to be assessed with 
caution.  For example, an individual should have a similar VO2 response to a similar exercise load 
during two separate tests (an expected finding), but VE could be higher in one trial and resulting in a 
higher FEO2 (13).  Alternatively, we could have exchanged the PPFS and Parvomedics at the midpoint 
during a series of prolonged exercise stages.  This approach would have eliminated day-to-day variation 
during submaximal data collections, but it would have introduced the distinct disadvantage of not being 
able to compare maximal responses; only one device could be used at a time to collect maximal exercise 
data.  Therefore, the approach that we selected appeared to be the best compromise.  However, although 
the data from our evaluation indicate that FEO2 values may differ, and the FECO2 values certainly differ, 
there is no way to conclusively prove this using the present data set. 
The difference between VO2max data obtained on the two devices is likely a limitation of the 
PPFS design.  If Qc measurements are not desired, the PPFS can be used without the extended mouth-
port adapter.  This should reduce the flow limitation and allow subjects to exercise to higher loads.  
However, because one of the objectives of the ISS study (16) was to measure Qc, this is not viewed as 
an ideal solution. 
It should be noted that throughout this report VO2 measured at maximal exertion during the peak 
cycle tests has been referred to as VO2max.  This is technically not the correct terminology for our 
measurement because we performed no specific verification of a plateau in VO2 with increasing work 
rates, which is the criterion for “true” VO2max (22).  However, not all individuals can attain this plateau, 
and previous comparisons have reported no statistically significant difference between VO2max and 
peak VO2, which is the correct description for the variable reported here.  Further, because the terms 
“VO2max” and “peak VO2” have been used interchangeably in various spaceflight and bed rest 
publications, we have chosen to use only VO2max in the description of test results contained in this 
report. 
CONCLUSIONS 
There were no findings in this evaluation that preclude using the PPFS to obtain data before, 
during, or after ISS missions.  In light of the differences observed in the VO2 and VCO2 measurements 
obtained by the PPFS and the Parvomedics devices, it is imperative that the same device be used for all 
pre-, in-, and post-flight testing if the data are to be compared across time points. 
• The differences observed in submaximal VO2 were small and are probably not clinically 
relevant. 
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• The differences observed in submaximal VCO2 are very likely due to differences in FECO2.  
Although FECO2 has only a small effect on the computation of VO2, the effect could confound 
any research projects that examine VCO2 as a variable of interest.  We recommend that PPFS 
expired gas fraction measurements be further examined. 
• The reduced VO2max and maximal work rate attained by the subjects during PPFS tests are 
likely due to a ventilatory flow limitation. 
• The reproducibility of the PPFS measurements should be quantified. 
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APPENDIX A – ACRONYM LIST 
BP Blood Pressure 
CO2 Carbon Dioxide 
ECWG Exploration Clinical Working Group 
FECO2 Fractions of Expired Carbon Dioxide 
FEO2 Fractions of Expired Oxygen 
HRP Human Research Program 
ISS International Space Station 
MOG Medical Operations Group 
NASA National Aeronautics and Space Administration 
O2 Oxygen 
PPFS Portable Pulmonary Function System 
Qc Cardiac Output 
SF6 Sulfur Hexafluoride 
SV Stroke Volume 
VE Expired Ventilation 
VCO2 Submaximal Carbon Dioxide 
VO2 Oxygen Consumption 
VO2max Maximal Oxygen Consumption 
W Watt 
 
